FRIMLEY, England, May 20 /PRNewswire/ --
FRIMLEY, England, May 20 /PRNewswire/ --
- Tasigna(R) (nilotinib) Effective in 77% of Patients Resistant or Intolerant to Prior Treatment in the Chronic (Early) Phase of Chronic Myeloid Leukaemia (CML)(1)
- Highly Targeted Nature of Tasigna(R) Tackles the Root Cause of CML Whilst Providing an Acceptable Tolerability Profile for Patients(1)(2)
- Tasigna Expands CML Portfolio for Novartis, Providing Effective Treatment Options for the Majority of Patients With Tasigna(R) and the CML Gold-Standard, Glivec(R)(imatinib)